{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:22:24Z","timestamp":1789024944372,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.seizure.2021.10.011","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T02:35:56Z","timestamp":1634610956000},"page":"111-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Long-term treatment with everolimus in TSC-associated therapy-resistant epilepsies"],"prefix":"10.1016","volume":"93","author":[{"given":"Gert","family":"Wiegand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodor W.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Stephani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navah E.","family":"Kadish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.seizure.2021.10.011_bib0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/ejpn.2001.0538","article-title":"Tuberous sclerosis complex: a review of neurological aspects","volume":"6","author":"Curatolo","year":"2002","journal-title":"Eur J Paediatr Neurol"},{"issue":"9639","key":"10.1016\/j.seizure.2021.10.011_bib0002","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.seizure.2021.10.011_bib0003","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/adc.2011.211995","article-title":"The Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for diagnosis and management","volume":"96","author":"Yates","year":"2011","journal-title":"Arch Dis Child"},{"issue":"23","key":"10.1016\/j.seizure.2021.10.011_bib0004","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","article-title":"Long-term treatment of epilepsy with everolimus in tuberous sclerosis","volume":"87","author":"Krueger","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.seizure.2021.10.011_bib0005","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejpn.2013.06.002","article-title":"Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?","volume":"17","author":"Wiegand","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"issue":"10056","key":"10.1016\/j.seizure.2021.10.011_bib0006","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2021.10.011_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107182","article-title":"Developmental outcomes in children\/adolescents and one adult with tuberous sclerosis complex (TSC) and refractory epilepsy treated with everolimus","volume":"111","author":"Kadish","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"12","key":"10.1016\/j.seizure.2021.10.011_bib0008","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/088307389801301206","article-title":"Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria","volume":"13","author":"Roach","year":"1998","journal-title":"J Child Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2021.10.011_bib0009","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2021.10.011_bib0010","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1212\/CPJ.0000000000000514","article-title":"Everolimus for treatment-refractory seizures in TSC: extension of a randomized controlled trial","volume":"8","author":"Franz","year":"2018","journal-title":"Neurol. Clin. Pract."},{"issue":"15","key":"10.1016\/j.seizure.2021.10.011_bib0011","first-page":"2","article-title":"Der elektronische Behandlungskalender (Epivista)","author":"Rabending","year":"2002","journal-title":"Z Epileptol"},{"key":"10.1016\/j.seizure.2021.10.011_bib0012","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.yebeh.2014.03.014","article-title":"Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam","volume":"34","author":"Strzelczyk","year":"2014","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.seizure.2021.10.011_bib0013","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejpn.2012.10.006","article-title":"Myoclonic astatic epilepsy (Doose syndrome) - a lamotrigine responsive epilepsy?","volume":"17","author":"Doege","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2021.10.011_bib0014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10309-009-0086-1","article-title":"Boor R. E-Health in der p\u00e4diatrischen Epileptologie","volume":"23","author":"Baudhuin","year":"2010","journal-title":"Z. Epileptol."},{"key":"10.1016\/j.seizure.2021.10.011_bib0015","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. https:\/\/ctep.cancer.gov."},{"key":"10.1016\/j.seizure.2021.10.011_bib0016","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/biomet\/42.1-2.80","article-title":"Some quick sign tests for trend in location and dispersion","volume":"42","author":"Cox","year":"1955","journal-title":"Biometrika"},{"issue":"1","key":"10.1016\/j.seizure.2021.10.011_bib0017","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-016-0530-z","article-title":"Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study","volume":"11","author":"Samueli","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.seizure.2021.10.011_bib0018","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejpn.2009.03.003","article-title":"Early control of seizures improves long-term outcome in children with tuberous sclerosis complex","volume":"14","author":"Bombardieri","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2021.10.011_bib0019","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"J\u00f3\u017awiak","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2021.10.011_bib0020","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.25956","article-title":"Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial","volume":"89","author":"Kotulska","year":"2021","journal-title":"Ann Neurol"},{"issue":"14","key":"10.1016\/j.seizure.2021.10.011_bib0021","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1177\/0883073817737446","article-title":"Predictors of drug-resistant epilepsy in tuberous sclerosis complex","volume":"32","author":"Jeong","year":"2017","journal-title":"J Child Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2021.10.011_bib0022","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/088307389701200203","article-title":"Cortical tuber count: a biomarker indicating neurologic severity of tuberous sclerosis complex","volume":"12","author":"Goodman","year":"1997","journal-title":"J Child Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2021.10.011_bib0023","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00381-019-04066-7","article-title":"Factors affecting epilepsy prognosis in patients with tuberous sclerosis","volume":"35","author":"G\u00fcl Mert","year":"2019","journal-title":"Childs Nerv Syst"},{"issue":"3","key":"10.1016\/j.seizure.2021.10.011_bib0024","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4068\/cmj.2011.47.3.150","article-title":"Clinical progress of epilepsy in children with tuberous sclerosis: prognostic factors for seizure outcome","volume":"47","author":"Park","year":"2011","journal-title":"Chonnam Med J"},{"issue":"4","key":"10.1016\/j.seizure.2021.10.011_bib0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/epi.12545","article-title":"Developmental brain abnormalities in tuberous sclerosis complex: a comparative tissue analysis of cortical tubers and perituberal cortex","volume":"55","author":"Ruppe","year":"2014","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2021.10.011_bib0026","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.seizure.2021.10.011_bib0027","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"issue":"19","key":"10.1016\/j.seizure.2021.10.011_bib0028","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"issue":"9861","key":"10.1016\/j.seizure.2021.10.011_bib0029","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"issue":"9869","key":"10.1016\/j.seizure.2021.10.011_bib0030","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121003393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121003393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:59:52Z","timestamp":1761011992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131121003393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":30,"alternative-id":["S1059131121003393"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2021.10.011","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term treatment with everolimus in TSC-associated therapy-resistant epilepsies","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2021.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}